Primary References


Ault, KA. "Human papillomavirus infections: diagnosis, treatment, and hope for a vaccine." Obstetrics and Gynecology Clinics of North America, 30 (4), Dec 2003: 809-17.


Baud, D, et al. "Immunogenicity against human papillomavirus type 16 virus-like particles is strongly enhanced by the PhoPc phenotype in Salmonella enterica serovar Typhimurium." Infectious Immunology, 72 (2), Feb 2004: 750-6.


Chen, YF, et al. "Cytotoxic-T-lymphocyte human papillomavirus type 16 E5 peptide with CpG-ologodeoxynucleotide can eliminate tumor growth in C57BL/6 mice." Journal of Virology, 78 (3), Feb 2004: 1333-43.


Franceschi, S, et al. "Prospects for primary prevention of cervical cancer in developing countries." Salud Publica Mexicana, 45 Suppl 3, 2003: S430-6.


Hallez, S. "Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia." Cancer Immunology and Immunotherapy, Feb 17 2004.


Herd, KA, et al. "Recombinant Kunjin virus replicon vaccines induce protective T-cell immunity against human papillomavirus 16 E7-expressing tumour." Virology, 319 (2), Feb 20 2004: 237-48.


Koutsky, Laura, et al. "A controlled trial of a human papillomavirus type 16 vaccine." The New England Journal of Medicine, 347 (21), Nov 21, 2002: 1645-1651.


Mandic, A. and T. Vujkov. "Human papillomavirus vaccine as a new way of preventing cervical cancer: a dream or the future?" Annals of Oncology, 15 (2), Feb 2004: 197-200.


Plummer, M, et al. "Strategies for HPV prevention." Virus Research,

89 (2), Nov 2002: 285-93.


Warzecha, H, et al. "Oral immunogenicity of human papillomavirus-like particles expressed in potato." Journal of Virology, 77(16), Aug 2003: 8702-11.